Rinvoq vs. Hadlima

Are Hadlima and Rinvoq the Same Thing?

Rinvoq (upadacitinib) and Hadlima (adalimumab-bwwd) are used to treat adults with moderately to severely active rheumatoid arthritis.

Hadlima is also used to treat juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).

Hadlima is biosimilar to Humira (adalimumab).

Rinvoq and Hadlima belong to different drug classes. Rinvoq is a Janus kinase (JAK) inhibitor and Hadlima is a tumor necrosis factor (TNF) blocker.

Side effects of Rinvoq and Hadlima that are similar include upper respiratory tract infections.

Side effects of Rinvoq that are different from Hadlima include nausea, cough, and fever.

Side effects of Hadlima that are different from Rinvoq include injection site reactions (redness, itching, bleeding, pain, and swelling), headache, and rash.

Both Rinvoq and Hadlima may interact with live vaccines.

Rinvoq may also interact with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).

Hadlima may also interact with abatacept, anakinra, warfarin, cyclosporine, and theophylline.

SLIDESHOW

What Is Rheumatoid Arthritis (RA)? Symptoms, Treatment, Diagnosis See Slideshow

What Are Possible Side Effects of Rinvoq?

Common side effects of Rinvoq include:

  • upper respiratory tract infections,
  • nausea,
  • cough, and
  • fever

What Are Possible Side Effects of Hadlima?

Side effects of Hadlima nclude<:/p>

  • infections (e.g. upper respiratory tract, sinusitis),
  • injection site reactions (redness, itching, bleeding, pain, and swelling),
  • headache, and
  • rash

What Is Rinvoq?

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

What Is Hadlima?

Hadlima (adalimumab-bwwd) is a tumor necrosis factor (TNF) blocker indicated for treatment of rheumatoid Arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps). Hadlima is biosimilar to Rituxan (adalimumab).

What Drugs Interact With Rinvoq?

Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.

What Drugs Interact With Hadlima?

Hadlima may interact with abatacept, anakinra, warfarin, cyclosporine, theophylline, and live vaccines.

How Should Rinvoq Be Taken?

The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

How Should Hadlima Be Taken?

The dose of Rituxan to treat adult rheumatoid arthritis and psoriatic arthritis is 50 mg once weekly with or without methotrexate (MTX). The dose of Rituxan to treat ankylosing spondylitis is 50 mg once weekly. The dose of Rituxan to treat adult plaque psoriasis is 50 mg twice weekly for 3 months, followed by 50 mg once weekly. The dose of Rituxan to treat pediatric plaque psoriasis or plaque psoriasis (patients who weigh 63 kg or more) is 50 mg once weekly.

QUESTION

The term arthritis refers to stiffness in the joints. See Answer
Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References


FDA. Rinvoq Product Information.

https://www.rinvoq.com

FDA. Hadlima Product Information.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761059s000lbl.pdf

Health Solutions From Our Sponsors